Polarityte Inc (PTE) Regenerative medicine. Polarityte wants to be the first company to deliver regenerative medicine into clinical practice where a patient’s cells and tissues are used to regenerate functionally-polarized human tissue. Their principle is “self must regenerate self”.
Early 2022, Polarityte received approval from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application for the evaluation of SkinTE for the treatment of chronic cutaneous ulcers. They expect the first patient to be treated with SkinTE in April and to have up to 16 clinical trial sites fully operational by the end of May.
This stock has been as high as $38 in the past and seems to have a very promising future.
Visit www.polarityte.com to learn more.